Testing effectiveness (Phase 2)Ended earlyNCT01151449
What this trial is testing
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer
Who this might be right for
Estrogen Receptor-negative Breast CancerHER2-negative Breast CancerMale Breast Cancer+7 more
National Cancer Institute (NCI) 6